ADADIn the search for such a countermeasure, monoclonal antibodies, a Nobel Prize-winning biotechnology developed in the 1970s, have become the first line of attack, pursued by at least 50 companies and academic teams. ADADOne thing is certain about monoclonal antibodies: If the pandemic keeps raging, there won’t be enough. Now, the reactors that make monoclonal antibodies are mostly occupied, making essential drugs for people with cancer and autoimmune diseases. But everyone was beaming.”Scaling it upTo turn that moment of triumph into a viable treatment, ongoing clinical trials will have to show that monoclonal antibodies are safe and effective, and determine the best dose. Monoclonal antibodies — potentially from many companies — will start to make the disease less dangerous.

Source: Washington Post September 30, 2020 15:02 UTC